Q-omics provides the consensus-scored EIF2AK3-DT profile across patient tissues and cancer cell-line models. EIF2AK3-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EIF2AK3-DT is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, EIF2AK3-DT RNA expression shows 20,917 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, THCA, and ACC as cancer lineages where EIF2AK3-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF2AK3-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF2AK3-DT survival associations across molecular data types. EIF2AK3-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF2AK3-DT RNA expression–survival associations across cancer types. High EIF2AK3-DT expression shows unfavorable associations in ACC, STAD and COAD, but favorable associations in MESO, UCS and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for EIF2AK3-DT RNA expression.
This table summarizes EIF2AK3-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for EIF2AK3-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF2AK3-DT shows lower tumor expression in THCA, KICH, UCEC and KIRC and higher tumor expression in HNSC and LIHC. The THCA box plot shows higher EIF2AK3-DT RNA expression in normal versus tumor tissue (log2 FC = −0.818, t-test p < 0.001).
This table shows molecular features associated with EIF2AK3-DT in patient tissues and cancer cell lines. In patient samples, EIF2AK3-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
